Abstract: Methods and systems for maintaining image quality are disclosed. A printing system and method is provided for maintaining image quality, comprising: initially establishing a plurality of image quality threshold standards; assigning an image quality threshold standard from the plurality of image quality threshold standards to an associated image job; comparing the assigned image quality threshold standard of each associated image job to a system check value; and, marking any image jobs having an assigned image quality threshold standard greater than the quality system check value.

Abstract: A system and method for configuring a customized sample job for monitoring print quality and increasing proofing flexibility. A sample job comprising one or more pages can be created in association with print programming attributes utilizing a document creation application. The sample job can be raster image processed with respect to a user specified job setting and stored in an electronic memory component (e.g., DFE component, computer memory, Flash memory, USB memory, etc) as a custom sample job. The custom sample job can then be selected with respect to a primary rendering job in order to render a sample page based on a predefined frequency interval (e.g., after every N sheets) to a sample tray. The frequency interval associated with the custom sample job production can be predefined on a job-by-job and/or global basis by a user.

Abstract: Methods and systems for maintaining image quality are disclosed. A printing system and method is provided for maintaining image quality, comprising: initially establishing a plurality of image quality threshold standards; assigning an image quality threshold standard from the plurality of image quality threshold standards to an associated image job; comparing the assigned image quality threshold standard of each associated image job to a system check value; and, marking any image jobs having an assigned image quality threshold standard greater than the quality system check value.

Abstract: Methods and systems for maintaining image quality are disclosed. A printing system and method is provided for maintaining image quality, comprising: initially establishing a plurality of image quality threshold standards; assigning an image quality threshold standard from the plurality of image quality threshold standards to an associated image critical job; comparing the assigned image quality threshold standard of each associated image critical job to a quality system check value; and, releasing and printing selected image critical jobs if the quality system check value is at least equal to the assigned image quality threshold standard.

Abstract: A system and method for configuring a customized sample job for monitoring print quality and increasing proofing flexibility. A sample job comprising one or more pages can be created in association with print programming attributes utilizing a document creation application. The sample job can be raster image processed with respect to a user specified job setting and stored in an electronic memory component (e.g., DFE component, computer memory, Flash memory, USB memory, etc) as a custom sample job. The custom sample job can be then selected with respect to a primary rendering job in order to render a sample page based on a predefined frequency interval (e.g., after every N sheets) to a sample tray. The frequency interval associated with the custom sample job production can be predefined on a job-by-job and/or global basis by a user.

Abstract: A novel method for assessing the risk of a cardiovascular event is provided. The concentration of 11-dehydro thromboxane in a urine sample is measured and compared to a set of standardized quartile concentrations. A concentration of urinary 11-dehydro thromboxane that falls within the fourth quartile is indicative of a greatly increased risk of a recurrent cardiovascular event.

Abstract: A novel method for detecting the concentration of a metabolite in a fluid sample is provided. Devices for the detection of the analyte are also provided. In particular, a device for determining the concentration of 11-dehydro thromboxane in a urine sample and comparing it to a set of standardized quartile concentrations is provided. A concentration of urinary 11-dehydro thromboxane that falls within the fourth quartile is indicative of a greatly increased risk of a recurrent cardiovascular event.

Abstract: The present invention provides compositions and methods for the treatment of cardiovascular diseases. More particularly, the present invention relates to modifying thrombus formation by administering an agent which, inter alia, is capable of (1) inactivating fluid-phase thrombin and thrombin which is bound either to fibrin in a clot or to some other surface by catalyzing antithrombin; and (2) inhibiting thrombin generation by catalyzing factor Xa inactivation by antithrombin III (ATIII). The compositions and methods of the present invention are particularly useful for preventing thrombosis in the circuit of cardiac bypass apparatus and in patients undergoing renal dialysis, and for treating patients suffering from or at risk of suffering from thrombus-related cardiovascular conditions, such as unstable angina, acute myocardial infraction (heart attack), cerebrovascular accidents (stroke), pulmonary embolism, deep vein thrombosis, arterial thrombosis, etc.

Abstract: The present invention relates to therapeutic methods for preventing or reducing neurological events utilizing a glycosaminoglycan and a serpin, including complexes and conjugates thereof. Methods of the present invention may be advantageous for preventing or reducing neurological events prior to, or during medical or surgical procedures, and after a neurological event. In particular, the present invention deals with neurological events associated with the generation of emboli that can lodge in the brain and/or cerebral circulation during cardiac surgery.

Abstract: A method for assessing aspirin resistance and relative risk of a cardiovascular event in a patient taking aspirin is provided. The concentration of 11-dehydro-thromboxane B2 in a urine sample is measured and compared to a set of standardized quartile concentrations. A concentration of urinary 11-dehydro-thromboxane B2 that falls within the second, third, or fourth quartile is indicative of aspirin resistance and an elevated risk of a recurrent cardiovascular event.

Abstract: The invention describes a method to automatically controlling, single channel Neuromuscular Electrical Stimulation (NMES) of the plantar muscle, in response to the sensing of motion of the foot or leg: to reduce accommodation of the stimulated plantar muscle and attendant reduction of contractions, which when undiminished increase blood flow for the prevention of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE); to turn off the stimulation during walking or running to prevent slips or falls; and to reduce power consumption of the unit that provides the stimulation.

Abstract: The present invention provides compositions and methods for the treatment of cardiovascular diseases. More particularly, the present invention relates to modifying thrombus formation by administering an agent which, inter alia, is capable of (1) inactivating fluid-phase thrombin and thrombin which is bound either to fibrin in a clot or to some other surface by catalyzing antithrombin; and (2) inhibiting thrombin generation by catalyzing factor Xa inactivation by antithrombin III (ATIII). The compositions and methods of the present invention are particularly useful for preventing thrombosis in the circuit of cardiac bypass apparatus and in patients undergoing renal dialysis, and for treating patients suffering from or at risk of suffering from thrombus-related cardiovascular conditions, such as unstable angina, acute myocardial infarction (heart attack), cerebrovascular accidents (stroke), pulmonary embolism, deep vein thrombosis, arterial thrombosis, etc.

Abstract: A novel method for detecting the concentration of a metabolite in a fluid sample is provided. Devices for the detection of the analyte are also provided. In particular, a device for determining the concentration of 11-dehydro thromboxane in a urine sample and comparing it to a set of standardized quartile concentrations is provided. A concentration of urinary 11-dehydro thromboxane that falls within the fourth quartile is indicative of a greatly increased risk of a recurrent cardiovascular event.

Abstract: A novel method for assessing the risk of a cardiovascular event is provided. The concentration of 11-dehydro thromboxane in a urine sample is measured and compared to a set of standardized quartile concentrations. A concentration of urinary 11-dehydro thromboxane that falls within the fourth quartile is indicative of a greatly increased risk of a recurrent cardiovascular event.

Abstract: The invention relates generally to compositions and methods for preventing or inhibiting thrombin generation or activity.

Abstract: A single channel neuromuscular electrical stimulation (NMES) device for the prevention of deep vein thrombosis (DVT), pulmonary embolism (PE), lower extremity edema, and other associated conditions by electrical stimulation of the muscles of the foot muscles. An electrical signal generator produces a square wave pattern of variable frequency, duration, intensity, ramp time, and stimulation on-off cycle. Surface electrodes are positioned over the foot muscles and are attached to the stimulator by various means. The stimulator is programmed in a manner to stimulate the foot muscles to reduce pooling of the blood in the soleal veins of the calf This is accomplished by only stimulating the soles of the feet.

Abstract: The present invention relates to compositions and methods for the treatment of diseases or conditions characterised by excess thrombin generation or activity. In particular, the invention provides combination compositions comprising low molecular weight heparin (LMWH) and low molecular weight dermatan sulphate (LMWDS). Such compositions are well suited for the treatment of said diseases or conditions, and they exert an effect which is greater than sum of the effects of LMWH and LMWDS if dosed as single agents, i.e. the combination composition exerts a synergistic effect.

Abstract: The present invention provides compositions and methods for the treatment of cardiovascular diseases. More particularly, the present invention relates to modifying thrombus formation by administering an agent which, inter alia, is capable of (1) inactivating fluid-phase thrombin and thrombin which is bound either to fibrin in a clot or to some other surface by catalyzing antithrombin; and (2) inhibiting thrombin generation by catalyzing factor Xa inactivation by antithrombin III (ATIII). The compositions and methods of the present invention are particularly useful for preventing thrombosis in the circuit of cardiac bypass apparatus and in patients undergoing renal dialysis, and for treating patients suffering from or at risk of suffering from thrombus-related cardiovascular conditions, such as unstable angina, acute myocardial infarction (heart attack), cerebrovascular accidents (stroke), pulmonary embolism, deep vein thrombosis, arterial thrombosis, etc.

Abstract: A method for diagnosing hyperhomocysteinemia by molecular genetic means is disclosed.

Abstract: The present invention provides compositions and methods for the treatment of cardiovascular diseases. More particularly, the present invention relates to modifying thrombus formation by administering an agent which, inter alia, is capable of (1) inactivating fluid-phase thrombin and thrombin which is bound either to fibrin in a clot or to some other surface by catalyzing antithrombin; and (2) inhibiting thrombin generation by catalyzing factor Xa inactivation by antithrombin III (ATIII). The compositions and methods of the present invention are particularly usefull for preventing thrombosis in the circuit of cardiac bypass apparatus and in patients undergoing renal dialysis, and for treating patients suffering from or at risk of suffering from thrombus-related cardiovascular conditions, such as unstable angina, acute myocardial infarction (heart attack), cerebrovascular accidents (stroke), pulmonary embolism, deep vein thrombosis, arterial thrombosis, etc.